XML 31 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
Equity
 3 Months Ended
Mar. 31, 2015
Equity [Abstract]  
Equity
Equity
Total equity as of March 31, 2015 increased $855.4 million compared to December 31, 2014. This increase was primarily driven by net income attributable to Biogen Inc. of $822.5 million and an increase in additional paid in capital resulting from our share-based compensation arrangements totaling $46.3 million.
Share Repurchases
In February 2011, our Board of Directors authorized the repurchase of up to 20.0 million shares of common stock. This authorization does not have an expiration date. During the three months ended March 31, 2015 and 2014, we did not repurchase any shares of common stock. As of March 31, 2015, approximately 1.3 million shares of our common stock remain available for repurchase under the 2011 authorization.
Noncontrolling Interests
The following table reconciles equity attributable to noncontrolling interests (NCI):
 
For the Three Months
Ended March 31,
(In millions)
2015
 
2014
NCI, beginning of period
$
5.0

 
$
0.6

Net income (loss) attributable to NCI, net of tax
(2.4
)
 
(0.2
)
Fair value of net assets and liabilities acquired and assigned to NCI
—

 
4.0

Translation adjustment and other
0.1

 
—

NCI, end of period
$
2.7

 
$
4.4